Journal of Oncology Pharmacy Practice最新文献

{"title":"A scoping review of renal function calculation methods for the dosing of carboplatin.","authors":"Michal Sladkowski, Melanie Dalby, Hannan Mahamud","doi":"10.1177/10781552261445381","DOIUrl":"https://doi.org/10.1177/10781552261445381","url":null,"abstract":"<p><p>BackgroundCarboplatin is widely used to treat solid and haematological malignancies. The Calvert formula (area under the curve (AUC)×(glomerular filtration rate (GFR) + 25) is used globally to calculate the dose. Due to the large number of methods available to calculate GFR it is possible that disparity exists for patients regarding their carboplatin dosing depending on the policy of the organisation treating them. The purpose of this scoping review is to determine the breadth and accuracy of GFR calculation methods used in the literature.MethodsMedline, Web of Science, Embase and CINAHL databases were searched in November 2024. Eligibility criteria included randomised controlled trials, case studies, case series and cohort studies that reported renal function calculation methods for the dosing of carboplatin. Accepted studies were written in English and conducted in adult or paediatric humans from 2000-2024. A combination of MeSH terms and keywords were used. Duplicates were removed. One author reviewed the articles by title and abstract and then by full text. The other authors provided a validation of 20% of selections at the title and abstract review stage and then at the full text stage. Data were extracted into an Excel spreadsheet and included the main author, year, study design, sample size, patient age, cancer type, GFR method and any relevant findings such as accuracy values.Results454 articles were identified, reduced to 102 after removing duplicates and exclusions applied. There were 41 different GFR methods reported. The most common were Cockcroft and Gault (C&G) using actual body weight (ABW), Jelliffe, CKD-EPIcreatinine, 24-h urine collection, Wright, MDRD and radionuclide techniques with either 99mTcDTPA or 51Cr EDTA. Whilst all papers reported the use of GFR methods only 26 reported comparisons to determine accuracy. Most papers used a reference GFR such as a radionuclide technique for comparison. A variety of comparison methods were used to measure accuracy such as mean (MPE), median (MdPE) and percentage errors (PE), bias and mean bias, coefficients and root-mean-squared error. C&G using ABW and Jelliffe generally overestimated renal function and had a wide dispersion of PE readings (-10-30.1 MPE and -9.5-9.55 MdPE respectively) suggesting low accuracy to the reference GFR. CKD-EPIcreatinine adjusted for body surface area (BSA) reported low MPE values (-2-0) suggesting good accuracy. This article reported an improvement when CKD-EPIcreatinine was adjusted for BSA whereas another reporting bias values showed the reverse. Wright and MDRD reported wide dispersion of MPE readings showing both over and underestimation compared with the reference GFR. While 14 articles mentioned 24-h collection, only two compared the accuracy to a reference. These reported MPE values of 35.9 and -25 showing large over and underestimation.ConclusionsThis review highlights a variety of methods used to calculate GFR for carboplatin dosing. Further ","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"10781552261445381"},"PeriodicalIF":0.9,"publicationDate":"2026-05-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147838900","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Errors in the dilution/reconstitution of injectable preparations in oncology: Analysis of the most common errors, clinical consequences, and technological solutions to ensure safe hospital practice.","authors":"Boufaress Soukaina, Cherif Chefchaouni Ali, Hafidi Youssef, El Kartouti Abddeslam, Bennani Ismail","doi":"10.1177/10781552261450121","DOIUrl":"https://doi.org/10.1177/10781552261450121","url":null,"abstract":"<p><p>ObjectiveThis review article was conducted to summarize the published literature on the most common errors and clinical consequences, and to explore technological solutions for securing the process of preparing chemotherapeutic drugs.Data sourceThe literature used in this review was identified through searches of major medical and pharmaceutical databases including (PubMed) (Science Direct). Articles were searched using the Medical Subject Headings terms: \"cytotoxic drugs\", \"compounding\", \"reconstitution errors\", \"oncology pharmacy\", \"chemotherapy preparation errors \"; \"automated compounding\"; \"dilution errors \".Summary of dataThe preparation of cytotoxic drugs has generally been centralized in the hospital pharmacy for two main reasons: to ensure the safety of staff, and to provide greater protection for patients. Errors in chemotherapy compounding have been identified, which can lead to severe outcomes, including death or permanent loss of function in patients with cancer. Such errors may occur during drug reconstitution and mixing, as well as during verification and labeling of the compounded mixture. Automated compounding systems have demonstrated the ability to prepare chemotherapy drugs effectively, delivering high-quality products with productivity comparable to that manual preparation methods.ConclusionCytotoxic drug reconstitution is a strategic link in oncology pharmacy to enhance safety, it is necessary to promote harmonized practices, develop continuing education, and integrate innovative technologies into preparation units.</p>","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"10781552261450121"},"PeriodicalIF":0.9,"publicationDate":"2026-05-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147839151","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Practical considerations in the management of patients with atrial fibrillation/flutter and hematologic malignancies.","authors":"Madeleine A Ochs, Nicholas Shabanowitz, Victoria R Nachar, Iman Ahmed, Salim S Hayek, Thomas Christopher Crawford, Sarah Lewis","doi":"10.1177/10781552261445449","DOIUrl":"https://doi.org/10.1177/10781552261445449","url":null,"abstract":"<p><p>ObjectiveThe purpose of this review is to highlight the nuanced approach for managing drug-drug interactions (DDIs), anticoagulation challenges, and overlapping toxicities in patients with atrial fibrillation (AF) and hematologic malignancies through patient case vignettes. While not all inclusive, these principles may be applicable to additional classes of medications not directly covered in this review.Data SourcesA comprehensive literature search was performed in PubMed to identify clinical trials, retrospective and population-based studies, pharmacokinetic analyses, and registry data evaluating atrial fibrillation management, anticoagulation strategies, and hematologic malignancy treatments.Data SummaryPatients with cancer, especially hematologic malignancies, have an increased risk of AF secondary to aging, overlapping risk factors, and cancer treatments and toxicities. In addition to the increased AF incidence, hematologic malignancies and their treatment increase the complexity of AF management. Mitigating drug-drug interactions (DDIs) between treatments for hematologic malignancies and AF, in particular antiarrhythmic drugs, is increasingly relevant as recent literature supports early rhythm control in patients with new-onset AF. Case-based scenarios highlight the importance of individualized decision making, especially for patients with high-risk hematologic malignancies, curative treatment intent, or significant cardiac comorbidity.ConclusionsManagement of AF in patients with hematologic malignancies requires an individualized multidisciplinary approach that carefully balances hematologic malignancy treatment intent, thromboembolic and bleeding risks, DDIs, and patient comorbidities to optimize both cardiovascular and malignancy outcomes.</p>","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"10781552261445449"},"PeriodicalIF":0.9,"publicationDate":"2026-05-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147839276","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-world predictors of severe chemotherapy-induced neutropenia in non-Hodgkin lymphoma: Evaluation of biosimilar and reference rituximab.","authors":"Dendhi Bagus Andriyanto, Nadia Farhanah Syafhan, Fitri Nurhayati","doi":"10.1177/10781552261450088","DOIUrl":"https://doi.org/10.1177/10781552261450088","url":null,"abstract":"<p><p>BackgroundThe adoption of rituximab biosimilars offers a cost-effective alternative for treating Non-Hodgkin Lymphoma (NHL). However, real-world safety data regarding severe hematological toxicities in the Indonesian clinical setting remains limited.ObjectiveTo evaluate and compare the incidence of severe neutropenia between reference rituximab and its biosimilar in patients with diffuse large B-cell lymphoma (DLBCL) receiving the R-CHOP regimen.MethodsA retrospective cohort study was conducted at a national referral hospital in Jakarta. We included 116 adult patients (Reference group n = 60; Biosimilar group n = 56) who completed six cycles of R-CHOP without product switching between 2019 and 2024. Severe neutropenia was defined as Grade 3 or 4 according to CTCAE criteria. Multivariate logistic regression was performed to identify independent risk factors.ResultsThe overall incidence of severe neutropenia was 62.9%. There was no statistically significant difference in the incidence of severe neutropenia between the reference and biosimilar groups (69.6% vs 56.7%; p = 0.148). Multivariate analysis revealed that male gender was the only independent predictor of severe neutropenia (aOR 2.34; 95% CI 1.05-5.24; p = 0.038), while poor performance status (ECOG ≥ 2) did not reach statistical significance (p = 0.151), regardless of the rituximab product used.ConclusionBiosimilar rituximab demonstrates a comparable safety profile to the reference product regarding severe neutropenia. Clinical monitoring should be prioritized for male patients to mitigate the risk of severe hematological toxicities during R-CHOP therapy.</p>","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"10781552261450088"},"PeriodicalIF":0.9,"publicationDate":"2026-05-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147839333","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Preliminary development and content validation of mopet-A multidomain oncology pain assessment tool for cancer care setting.","authors":"Manjula Gudhoor, Shrinivas Sonwalkar, Maheen Khazi, Riddhi Patel, M S Ganachari","doi":"10.1177/10781552261448822","DOIUrl":"https://doi.org/10.1177/10781552261448822","url":null,"abstract":"<p><p>PurposeCancer pain affects emotional, behavioural, social, and financial well-being beyond physical symptoms. Preliminary development and to perform content validation of a Multidomain Oncology Pain Assessment Tool incorporating physical, emotional, behavioural, sleep-related, social, and financial domains, grounded in the biopsychosocial model of pain.MethodsMixed-method study design was used to develop and validate a pain assessment questionnaire. In the qualitative phase, focus group discussion, interviews, and expert panel reviews were conducted to generate and refine questionnaire items, ensuring cultural relevance and content validity. In the quantitative phase, healthcare professionals participated in the validation, with reliability assessed via Cronbach's alpha and content validity evaluated using S-CVI/avg scores.ResultsIn this preliminary content validation, the tool demonstrated excellent internal consistency (Cronbach's α = 0.84-0.94) and strong expert-rated content validity (S-CVI/avg > 0.90). The inclusion of behavioural changes, emotional withdrawal, sleep disturbances, and financial burden ensured a holistic reflection of patients' lived experiences.ConclusionsThis preliminarily validated tool provides a structured, multidimensional, patient-centred framework for assessing cancer-related pain. Further construct validity, criterion validity, and patient-level pilot testing are warranted before broader clinical deployment. Its multidimensional approach supports both pharmacological and non-pharmacological strategies, enabling more accurate and compassionate pain management. Broader multi-centre validation is recommended to strengthen its applicability in diverse clinical settings.</p>","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"10781552261448822"},"PeriodicalIF":0.9,"publicationDate":"2026-05-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147839296","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cervical cancer and human papillomavirus (HPV) vaccination awareness Among university students: A global scoping review of knowledge, attitudes, and barriers.","authors":"Shwetha Cv, G Hari Prakash, Tejaswini B Darukaradhya","doi":"10.1177/10781552261446556","DOIUrl":"https://doi.org/10.1177/10781552261446556","url":null,"abstract":"<p><p>BackgroundCervical cancer remains a significant global public health burden, particularly in low- and middle-income countries (LMICs), with Human Papillomavirus (HPV) vaccination emerging as a critical preventive strategy. University students represent a key demographic for vaccination interventions given their reproductive health significance and potential role as future healthcare advocates.ObjectivesTo comprehensively synthesize global evidence on cervical cancer and HPV vaccination knowledge, attitudes, and barriers among university students.MethodsA scoping review following PRISMA-ScR guidelines was conducted using literature from databases like PubMed and Scopus (2021-2025). Eighteen cross-sectional observational studies from multiple countries were included, focusing on university students exclusively. Data were extracted using a standardized Population-Concept-Context framework and synthesized narratively.ResultsAcross 18 studies (N = 11,500 students), cervical cancer awareness ranged from 59% to 90%, whereas HPV awareness was lower and more variable (18-91%). Adequate HPV knowledge ranged from 20.7% to 72.7%, and vaccine related knowledge from 18.9% to 59.8%. Positive attitudes toward HPV vaccination ranged from 36% to 75%, while vaccine uptake remained low (0-35%). Common barriers included safety concerns (50-63%), misconceptions (42-43%), insufficient information (18-33%), and low perceived susceptibility (4-40%).ConclusionsSubstantial evidence practice gaps exist among university students regarding cervical cancer prevention. Targeted educational interventions addressing misconceptions, enhancing safety communications, and leveraging university students' academic backgrounds as future healthcare leaders are essential to increase HPV vaccination uptake and reduce cervical cancer burden globally.</p>","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"10781552261446556"},"PeriodicalIF":0.9,"publicationDate":"2026-05-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147838943","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluating real-world use of resuscitation cart medications to guide evidence-based and resource-efficient practice at a comprehensive cancer center.","authors":"Asma'a A Al-Kharabsheh, Haya Kasabi, Enas Al-Kurdi, Fatima Awaddallah, Noor I Nassar, Naser Mahmoud, Lama H Nazer","doi":"10.1177/10781552261447897","DOIUrl":"https://doi.org/10.1177/10781552261447897","url":null,"abstract":"<p><p>Aim of the StudyResuscitation carts are essential for ensuring rapid access to life-saving medications during cardiopulmonary resuscitation (CPR). However, limited guidance exists on which medications to include. This study aims to determine the essential medications for inclusion in a resuscitation cart, based on the utilization and evidence-based recommendations.MethodsThis is a retrospective study for adult cancer patients who underwent CPR between March 2023 and March 2024. Medications utilized during CPR were collected from electronic medical records. Based on clinical guidelines and utilization rates, medications were categorized into three groups: Group A, medications utilized during CPR and/or with strong evidence to include, and kept with no change, Group B, essential medications but requiring quantity modifications, and (C) non-essential medications or not utilized during CPR and were removed. Pharmacy working hours needed for carts maintenance processes were evaluated before and after the change.ResultsA total of 881 CPRs were performed during the study period. Among the 25 medications included in the carts, 11 were classified in group A, 2 in group B, and 12 in group C. Based on the available data, the total number of medications in the resuscitation carts was reduced to 13 medications. This reduced cart maintenance time from 602 to 241 h annually.ConclusionOptimizing resuscitation cart medications using evidence and utilization data can effectively reduce the number of medications, time required for cart management, and medication waste. Future research may explore other patient populations, to support the development of universal guidance on resuscitation cart medication content.</p>","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"10781552261447897"},"PeriodicalIF":0.9,"publicationDate":"2026-05-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147839171","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Immune-Mediated upper gastrointestinal toxicities reported With immune checkpoint inhibitors: An analysis of the food and drug administration adverse event reporting system (FAERS).","authors":"Emir Cerme, Murad Guliyev, Vali Aliyev, Zeliha Birsin, Murat Günaltılı, Mehmet Cem Fidan, Selin Cebeci, Seda Jeral, Hamza Abbasov, Nebi Serkan Demirci, Ozkan Alan","doi":"10.1177/10781552261447836","DOIUrl":"https://doi.org/10.1177/10781552261447836","url":null,"abstract":"<p><p>PurposeThis study aimed to characterize FAERS reports of immune-mediated upper gastrointestinal (GI) toxicities associated with immune checkpoint inhibitors and to explore disproportional reporting patterns across ICI classes and treatment regimens.MethodsInput data were downloaded from the public release of the FDA database including time period between January 1 2016, and December 31, 2024. 132 patients with upper-GI toxicity were included. Categorical variables were compared using either the chi-square test or Fisher's exact test. To evaluate the potential association between ICIs and specific upper-GI toxicity events of interest, a disproportionality analysis was conducted using the Reporting Odds Ratio (ROR) method. A signal was considered statistically significant when the lower bound of the 95% confidence interval for the ROR exceeded 1.0.ResultsAnti-PD-1 agents showed higher disproportional reporting of upper-GI toxicities compared to anti-PD-L1 (p = 0.001, ROR = 3.83 95% CI: 1.53-15.23). A higher proportion of hospitalization among reported cases were observed in patients treated with concurrent chemotherapy, compared to those did not receive chemotherapy (ROR = 2.5; 95% CI: 1.05-5.921; p = 0.045).ConclusionAnti-PD-1 therapy showed a stronger reporting signal for upper-GI toxicity than anti-PD-L1 therapy in FAERS, although the number of anti-PD-L1 cases was small. Concurrent chemotherapy was associated with a higher proportion of hospitalization among reported cases. These findings are exploratory and hypothesis-generating.</p>","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"10781552261447836"},"PeriodicalIF":0.9,"publicationDate":"2026-05-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147839182","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pharmacist's role in the validation of chemotherapy prescriptions.","authors":"Asma Ben Romdhane, Yosra ElFidha, Emna Jaoued, Houda Bouattour, Dora Cherif","doi":"10.1177/10781552261447210","DOIUrl":"https://doi.org/10.1177/10781552261447210","url":null,"abstract":"<p><p>IntroductionThe complexity of chemotherapy protocols and the narrow therapeutic index of anticancer drugs make the risk of medication errors particularly high in oncology. This study analyzed and categorized pharmaceutical interventions related to chemotherapy prescriptions in a clinical hematology center.MethodsThis study was conducted in a specialized clinical hematology center over a defined study period (16 months). All chemotherapy prescriptions validated by clinical pharmacists were reviewed. Validation was performed according to both regulatory and scientific criteria. Identified therapy-related problems were discussed with physicians, and all pharmaceutical interventions were recorded and classified according to the ReMeD severity scale.ResultsA total of 6186 chemotherapy prescriptions were analyzed, leading to 117 pharmaceutical interventions. The most common errors involved dosage errors (n = 51;49.03%), omission of prescription (n = 23;22.11%) and incorrect treatment duration (n = 11;10.57%). Most interventions were rated as having a major clinical impact, particularly those preventing omission and posology errors, ensuring optimal chemotherapy management and patient safety. All interventions were accepted by physicians, highlighting strong interdisciplinary collaboration.ConclusionPharmaceutical interventions represent a key component in improving the safety and quality of chemotherapy management. Strengthening the pharmacist's integration into oncology teams ensures better therapeutic outcomes, reduces medication-related risks, and supports a culture of safe and evidence-based cancer care.</p>","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"10781552261447210"},"PeriodicalIF":0.9,"publicationDate":"2026-05-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147839189","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Stability of extemporaneously compounded cobimetinib oral suspensions.","authors":"Sophia Tilley, Yong Li, Cynthia A Brasher, Mary Ashley Rimmer, Tharindu A Ranathunge, Shea Mercer, Lei Yang, M Brooke Bernhardt","doi":"10.1177/10781552261449183","DOIUrl":"https://doi.org/10.1177/10781552261449183","url":null,"abstract":"<p><p>IntroductionThe stability of cobimetinib prepared in a simple aqueous suspension was evaluated. This evaluation aimed to determine how well the compound maintains its integrity over time in a non-complex vehicle for pediatric applications. By monitoring concentration and purity over a defined period, the study provides insight into optimal storage conditions and potential limitations of the preparation.MethodsCobimetinib tablets were dispersed in purified water to prepare oral suspensions with final concentrations of 1 mg/mL and 12 mg/mL. Each suspension was equally aliquoted and stored under two conditions: room temperature (20 ± 2 °C) and refrigerated conditions (4 °C) (n = 3 per condition). Samples were prepared and analyzed at predefined time points (days 0, 1, 2, 3, 7, 9, and 14) to evaluate stability over time. Physical stability was assessed by pH measurement, as well as visual inspection. Cobimetinib concentrations were quantified using ultra-performance liquid chromatography coupled with ultraviolet detection and mass spectrometry (UPLC-UV-MS).ResultsNo changes in pH were observed throughout the study. Visual inspections revealed no color change. The cobimetinib oral suspensions at concentrations of 1 mg/mL and 12 mg/mL retained 90 to 110% of their initial concentrations over 14 days when stored at both room temperature and 4 °C.ConclusionThe extemporaneously compounded cobimetinib oral suspensions, at concentrations of 1 mg/mL and 12 mg/mL, demonstrated acceptable stability for up to 14 days under both room temperature and 4 °C. These findings support its potential as a viable alternative dosage form for short-term use in clinical settings.</p>","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"10781552261449183"},"PeriodicalIF":0.9,"publicationDate":"2026-05-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147839292","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}